ABCAM Logo
GB00B6774699
A1C605
ABC.L

ABCAM

Loading quotes...

Forecast

Buy
  1
Hold
  4
Sell
  0

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2020, ABCAM has already paid €0.0406 in dividends. The last payout was in April 2020.

Financials

In the last year, ABCAM had revenue of €290.59M and net profit of €163.64M
(EUR) 2024
YoY
Revenue 290.59M 33.11%
Gross profit 120.18M 60.13%
Net profit 163.64M 225.84%
EBITDA 215.36M 1,342.59%

Fundamentals

Metric Value
Market capitalization
€4.56B
Number of shares
230.15M
52-week high/low
€19.81 - €19.81
Dividends No
Beta
0.86
P/E ratio
578.30
PEG ratio
5.78
P/B ratio
3.88
P/S ratio
0.00

Company profile

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Name
ABCAM
CEO
Markus Lusser
Headquarters Cambridge,
United Kingdom
Website
Sector
Health Care
Industry
Life Sciences Tools & Services
IPO
11/03/2005
Employees 1,760

Ticker symbols

Exchange Symbol
London Stock Exchange
ABC.L
Pnk
ABCZF
🍪

Parqet  uses cookies. Learn more